Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;30(6):3473-3485.
doi: 10.1007/s00330-019-06640-8. Epub 2020 Feb 11.

The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC

Shu-Ling Chen #  1 , Han Xiao #  1 , Zong-Lin Xie  2 , Jing-Xian Shen  3 , Ze-Bin Chen  4 , Yuan-Qi Wang  5 , Bin Li  6 , Zhen-Wei Peng  6   7 , Ming Kuang  1   4 , Jia-Ming Lai  8 , Sui Peng  9   10
Affiliations

The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC

Shu-Ling Chen et al. Eur Radiol. 2020 Jun.

Abstract

Objectives: We used the status of microvascular invasion (MVI) at primary resection to help treatment selection for hepatitis B virus-positive (HBV+) recurrent hepatocellular carcinoma (rHCC) patients in Barcelona Clinic Liver Cancer (BCLC) stage B-C.

Methods: From 2009 to 2017, we enrolled 221 consecutive HBV+ rHCC patients at BCLC stage B-C who underwent re-resection (RR), radiofrequency ablation (RFA), or transarterial chemoembolization (TACE). Post recurrence survival (PRS) and overall survival (OS) were compared between RR/RFA and TACE according to MVI status. A one-to-one propensity score matching analysis was performed.

Results: For MVI(-) patients, the median PRS was 62.3 months for the RR/RFA group and 21.1 months for the TACE group (p = 0.039). The corresponding OS was 71.4 months and 26.6 months, respectively (p = 0.010). For MVI(+) patients, the median PRS in the RR/RFA group and TACE group was 14.7 months and 10.1 months (p = 0.115). The corresponding OS was 23.4 months and 16.4 months, respectively (p = 0.067). After matching, the dominance of RR/RFA over TACE remained in MVI(-) patients for both PRS (62.3 months vs 15.3 months, p = 0.019) and OS (98.1 months vs 33.4 months, p = 0.046). No significant difference was found in MVI(+) patients for either PRS (14.7 months vs 11.8 months, p = 0.593) or OS (23.4 months vs 28.1 months, p = 0.662).

Conclusions: MVI status definitely helps select treatment options in HBV+ rHCC patients. For MVI(-) patients, RR/RFA provided better survival than TACE while for MVI(+) patients, TACE shared similar survival outcomes.

Key points: • This study aimed at the determination of the optimal treatment options (ablation /resection vs TACE) in case of recurrent HBV-related HCC. • It showed that MVI status, established at primary resection of HCC, was a powerful marker for selecting the best treatment option in these patients. • In MVI(-) patients, RR/RFA achieved a better survival than TACE. In MVI(+) patients, TACE shared similar survival.

Keywords: Carcinoma, hepatocellular; Chemoembolization, therapeutic; Hepatectomy; Radiofrequency ablation; Recurrence.

PubMed Disclaimer

References

    1. Koh PS, Chan ACY, Cheung TT et al (2016) Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB (Oxford) 18:72–78. https://doi.org/10.1016/j.hpb.2015.07.005 - DOI
    1. Dai WC, Cheung TT (2016) Strategic overview on the best treatment option for intrahepaitc hepatocellular carcinoma recurrence. Expert Rev Anticancer Ther 16:1063–1072. https://doi.org/10.1080/14737140.2016.1226136 - DOI - PubMed
    1. Joliat G-R, Allemann P, Labgaa I et al (2017) Treatment and outcomes of recurrent hepatocellular carcinomas. Langenbecks Arch Surg 402:1–8. https://doi.org/10.1007/s00423-017-1582-9 - DOI
    1. Imamura H, Matsuyama Y, Tanaka E et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207 - DOI
    1. Tung-Ping Poon R, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24. https://doi.org/10.1097/00000658-200007000-00003 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources